Analysis of Potential Genotoxic Impurities in Active Pharmaceutical Ingredients (3) - Analysis of Haloalcohols and Glycidol Part 1-

Importance of the topic

The presence of haloalcohols and glycidol as potential genotoxic impurities in pharmaceutical products poses significant safety concerns.
These low‐molecular‐weight compounds are used in drug synthesis and can remain as trace contaminants, carrying carcinogenic risks for patients.
Reliable detection at sub‐ppm levels is essential to meet regulatory guidelines and ensure product safety.

Objectives and study overview

This study demonstrates a sensitive GC‐MS method to quantify 2‐chloroethanol, 2‐bromoethanol, 2‐iodoethanol and glycidol in active pharmaceutical ingredients (APIs).
The aim is to optimize sample preparation and chromatographic parameters to achieve low detection limits while minimizing matrix interference.

Methodology and used instrumentation

Sample preparation employs trimethylsilyl (TMS) derivatization to convert polar haloalcohols and glycidol into volatile derivatives.
APIs are dissolved in pyridine (25 mg/mL), spiked with 1,1,2,2‐bromoethanol‐D4 internal standard, and treated with BSTFA at 70 °C for 30 minutes.
Derivatized analytes are extracted into dichloromethane, dried over sodium sulfate and injected into the GC‐MS.

Used instrumentation

• GC‐MS system: Shimadzu GCMS‐QP2010 Ultra
• Capillary column: Rtx‐200, 30 m × 0.25 mm I.D., 0.25 μm film
• Injection: Split mode (1 µL, split ratio 30), inlet 280 °C
• Oven program: 50 °C (5 min) → 10 °C/min to 100 °C → 20 °C/min to 320 °C (3 min)
• MS: Fast Automated Scan/SIM (FASST) with scan range m/z 30–450; SIM transitions optimized for each TMS derivative

Main results and discussion

The method achieved baseline separation of all TMS derivatives within a 10 minute runtime.
Calibration at 25 µg/mL standard (equivalent to 1000 ng/mg in API) produced sharp peaks and reproducible retention times.
Sensitivity enabled detection limits well below regulatory thresholds for genotoxic impurities.
Scan and SIM spectra confirmed the identity of each derivative, with major ions at m/z 93/95 for 2‐chloroethanol‐TMS, 181/183 for 2‐bromoethanol‐TMS, 185/229 for 2‐iodoethanol‐TMS, and 101/59 for glycidol‐TMS.

Benefits and practical applications

This GC‐MS approach provides pharmaceutical laboratories with a robust tool for routine screening of genotoxic impurities.
Trimethylsilyl derivatization enhances volatility and chromatographic performance, reducing API matrix effects.
The combined scan/SIM acquisition ensures both qualitative confirmation and quantitative accuracy.

Future trends and potential applications

Advances in two‐dimensional GC and high‐resolution MS may further improve selectivity and reduce analysis time.
Automated sample preparation platforms could streamline derivatization and extraction workflows.
Integration with risk assessment models will support stricter control of trace impurities in complex formulations.

Conclusion

The presented GC‐MS method with TMS derivatization reliably quantifies haloalcohols and glycidol at trace levels in APIs.
High sensitivity, specificity and throughput make it a valuable asset for quality control in pharmaceutical development and manufacturing.

Reference

Frank David, Karine Jacq, Pat Sandra, Andrew Baker, Matthew S. Klee: Analysis of potential genotoxic impurities in pharmaceuticals by two-dimensional gas chromatography with Deans switching and independent column temperature control using a low-thermal-mass oven module, Anal Bioanal Chem, 396, 1291–1300 (2010)